Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision pending resolution of clinical hold with FDA

Conditions

Mycobacterium Avium Complex
Non-tuberculous Mycobacterium Pulmonary Disease

Interventions

DRUG: SPR720
DRUG: Placebo
DRUG: Open-label Standard of Care

Sponsor

Spero Therapeutics